BioNotebook: Deals from Five Prime/GSK, Actavis/Rhythm, Apricus/Forendo; a DARPA collaboration and IPO news

 
• By Mandy Jackson

Five Prime, GSK expand collaboration; Actavis gains option to buy Rhythm subsidiary; Apricus licenses fispemifene from Forendo; Inovio, MedImmune partner with DARPA money; and IPO updates from DBV, Coherus, S1 Biopharma and Tobira.

More from Alimentary/Metabolic

More from Therapy Areas